---
title: "12 Health Care Stocks Moving In Friday's Pre-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293034351.md"
description: "In Friday's pre-market session, healthcare stocks showed mixed movements. Gainers included Anixa Biosciences (+10.0%), Barinthus Biotherapeutics (+8.65%), and Anteris Technologies (+7.67%). Conversely, significant losers featured Regenxbio (-19.5%), Liminatus Pharma (-17.0%), and Kairos Pharma (-15.86%). The report highlights specific percentage changes and market capitalizations for these listed companies."
datetime: "2026-07-17T12:05:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293034351.md)
  - [en](https://longbridge.com/en/news/293034351.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293034351.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Friday's Pre-Market Session

### Gainers

-   **Anixa Biosciences** (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market session. The market value of their outstanding shares is at $112.9 million.
-   **Barinthus Biotherapeutics** (NASDAQ:BRNS) stock increased by 8.65% to $0.73. The company's market cap stands at $27.3 million.
-   **Anteris Technologies Glb** (NASDAQ:AVR) stock rose 7.67% to $8.98. The company's market cap stands at $811.8 million.
-   **Genenta Science** (NASDAQ:GNTA) shares increased by 7.63% to $1.55. The company's market cap stands at $33.7 million.
-   **Jaguar Health** (NASDAQ:JAGX) shares increased by 7.11% to $1.43. The company's market cap stands at $6.5 million.
-   **Beyond Air** (NASDAQ:XAIR) shares rose 7.02% to $5.94. The company's market cap stands at $3.9 million.

### Losers

-   **Regenxbio** (NASDAQ:RGNX) shares fell 19.5% to $9.02 during Friday's pre-market session. The company's market cap stands at $579.0 million.
-   **Liminatus Pharma** (NASDAQ:LIMN) shares decreased by 17.0% to $0.12. The market value of their outstanding shares is at $9.9 million.
-   **Kairos Pharma** (AMEX:KAPA) stock declined by 15.86% to $0.29. The market value of their outstanding shares is at $7.2 million.
-   **Agape ATP** (NASDAQ:ATPC) shares decreased by 15.48% to $3.55. The company's market cap stands at $4.2 million.
-   **Jasper Therapeutics** (NASDAQ:JSPR) shares declined by 12.4% to $0.68. The company's market cap stands at $21.6 million.
-   **Protalix BioTherapeutics** (AMEX:PLX) stock decreased by 12.13% to $2.03. The market value of their outstanding shares is at $186.1 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [LIMN.US](https://longbridge.com/en/quote/LIMN.US.md)
- [RGNX.US](https://longbridge.com/en/quote/RGNX.US.md)
- [ANIX.US](https://longbridge.com/en/quote/ANIX.US.md)
- [BRNS.US](https://longbridge.com/en/quote/BRNS.US.md)
- [KAPA.US](https://longbridge.com/en/quote/KAPA.US.md)
- [AVR.US](https://longbridge.com/en/quote/AVR.US.md)
- [GNTA.US](https://longbridge.com/en/quote/GNTA.US.md)
- [JAGX.US](https://longbridge.com/en/quote/JAGX.US.md)
- [XAIR.US](https://longbridge.com/en/quote/XAIR.US.md)
- [ATPC.US](https://longbridge.com/en/quote/ATPC.US.md)
- [JSPR.US](https://longbridge.com/en/quote/JSPR.US.md)
- [PLX.US](https://longbridge.com/en/quote/PLX.US.md)
- [LIMNW.US](https://longbridge.com/en/quote/LIMNW.US.md)

## Related News & Research

- [Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference | ANIX Stock News](https://longbridge.com/en/news/296231345.md)
- [Liminatus Pharma annual meeting draws 48.31% of shares represented](https://longbridge.com/en/news/294876806.md)
- [Bit Origin To Implement 1-For-5 Reverse Stock Split To Meet Nasdaq Requirements](https://longbridge.com/en/news/296359463.md)
- [REGENXBIO (NASDAQ:RGNX) Issues Earnings Results, Beats Expectations By $0.35 EPS](https://longbridge.com/en/news/295177397.md)
- [L1 Capital reports $4.11 million Anteris Technologies share disposal](https://longbridge.com/en/news/295093404.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**